Our vision is to employ new dual-acting retinoic acid receptor modulators (RAR-M) as the basis for developing a new rational effective treatment approach for ALS and meet that unmet need. In the longer term, we see a great opportunity to use our IP from the ALS arena to move on to target the wider range of neurodegenerative diseases.
The Science Behind specialise in integrating cutting-edge non-invasive neurostimulation and neuroimaging technologies and services to enhance Phase I clinical trials.
Innovatively applying techniques such as transcranial magnetic stimulation (TMS), quantitative sensory testing (QST) and electroencephalography (EEG), either independently or in combination with cognitive or physiological assessments, The Science Behind excels in addressing crucial questions related to target engagement, dose response and the timing of efficacy.
Our approach provides information on how a drug impacts various aspects of central nervous system function. This deeper insight into the neural mechanisms of drug action in humans serves to guide the development of new treatments, potentially enhancing their prospects for success in future clinical trials.
